Denver, Colorado, 80230, United States
NCT Number: NCT00339872
Study Evaluating IMA-638 in Asthma
The purpose of this study is to evaluate the safety of, and blood drug levels for, single, ascending doses of IMA-638 in mild to moderate asthma subjects.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–50 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Men and women of non-childbearing potential with mild to moderate asthma as defined by forced expiratory volume in 1 second (FEV1) greater than 70% predicted.
- Well controlled asthma, as exhibited by completion of asthma questionnaire.
- Otherwise healthy, except for asthma.
Treatment and study plan
IMA-638
DrugPrimary outcomes
-
Safety will be measured by evaluating physical examinations, spirometry, vital signs, electrocardiograms (ECGs), and clinical laboratory test results.
Secondary outcomes
-
Drug levels in the blood and associated biomarkers will be evaluated.
Interested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Registry information
Official study title
Randomized, Double-Blind, Placebo-Controlled, Sequential-Group, Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IMA-638 Administered Subcutaneously and Intravenously to Subjects With Asthma
Important dates
- Study start
- 2006
- Study completion
- 2007
- First posted
- Jun 21, 2006
- Registry last updated
- Dec 5, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients
NCT02227394
Asthma, Asthma Bronchial
Edegem, Antwerp, Belgium
View Trial DetailsDetection of Cav1 Calcium Channels in Inflammatory Cells of Asthmatic Children
NCT02809560
Asthma, Bronchial Diseases
Toulouse, France
View Trial DetailsCAMP Air: Efficacy and Cost-effectiveness in Urban Adolescents
NCT05091034
Asthma, Bronchial Diseases
New York, United States
View Trial DetailsPrimary Care Asthma FeNO Trial
NCT05853809
Asthma, Bronchial Diseases
Stockholm, Sweden
View Trial Details